Host Cell Protein (HCP) ELISA

The Host Cell Protein (HCP) ELISA is a multi-analyte sandwich immunoassay that, once qualified and validated for a specific process, is the gold-standard method for total HCP measurement. As the gold-standard method for total HCP measurement, it is central to ensuring product purity and mitigating immunogenicity risks.

• Legacy Technique: SDS-PAGE with silver staining and 2D-PAGE with immunoblotting. These methods could visualize protein impurity profiles but were not broadly quantitative, lacked sensitivity, and could not definitively identify proteins as host-cell derived.
• Established Standard: Process-Specific Polyclonal ELISA. The current industry and regulatory gold standard is a sandwich ELISA developed using polyclonal antibodies raised against a null cell line mock run (i.e., the host cells put through the purification process without the product-expressing gene). This makes the assay specific to the process.
• Emerging Orthogonal Methods: Mass Spectrometry (LC-MS/MS) is increasingly used to characterize HCP populations and assess ELISA reagent coverage. While not currently accepted as a standalone quantitative method for release, targeted MS approaches are being explored to supplement or eventually replace ELISA for high-risk HCPs.

The HCP ELISA is a multi-analyte sandwich immunoassay. Unlike assays for a single analyte, this method aims to detect as many distinct HCPs as possible using polyclonal antibody reagents.

• Output: Total HCP concentration (e.g., ng/mL), interpolated from the standard curve.

• Normalization: Reported per mg of product (e.g., ng HCP/mg therapeutic protein or AAV capsid).

• Interpretation: Results exceeding acceptance criteria (e.g., NMT 10 ng/mg) trigger batch rejection or investigation into purification performance.

• High Sensitivity: Capable of detecting total HCPs at the low nanogram-per-milligram levels required for product safety.
• Quantitative: Provides a single, quantitative value for an extremely complex mixture of impurities.
• Regulatory Acceptance: The established, gold-standard method that is universally accepted by global health authorities for lot release.

Incomplete Coverage: Polyclonal antibodies may not bind all HCPs—especially poorly immunogenic ones. Thus, coverage analysis using orthogonal methods—most often LC-MS/MS, with or without supplemental 2D-Western blot—is now a regulatory expectation to quantify how much of the HCP population the ELISA can detect.

The assay quantifies a complex mixture of hundreds of different proteins against a standard that is also a complex mixture. The resulting "ng/mg" value is therefore a relative measure of total immunoreactivity rather than a true mass concentration, a fact that is well-understood by regulators.
Dilution & Matrix Effects: The assay is highly sensitive to the sample dilution factor. The product itself or other matrix components can interfere with the assay, requiring careful development to find a dilution that is linear and provides an accurate measurement.

Validation follows the principles of ICH Q2(R2) and the specific expectations of USP <1132>.

• Reagent Characterization & Coverage: This is the most critical and unique aspect. The polyclonal antibody reagent must be well-characterized. Its coverage—the percentage of total HCPs it can detect—must be assessed using a 2D-Western Blot or Mass Spectrometry. A high coverage percentage is expected by regulators.
• Specificity: The assay must show minimal cross-reactivity to the drug product itself.
• Accuracy for HCP ELISAs is challenging because the analyte is a heterogeneous population of hundreds of proteins with varying immunoreactivity. Unlike single-analyte assays, it is not possible to prepare a spike that fully represents the true HCP population present in a process sample. Therefore, accuracy is most commonly inferred by dilutional linearity, demonstrating that measured HCP concentration is independent of dilution and that the sample dilution curve is parallel to the reference standard curve. Where a representative HCP reference preparation is available, spike/recovery experiments may also be performed, but results must be interpreted cautiously given the limited representativeness of any standard.

Standardization of HCP ELISA methods requires careful control of antibody generation, assay format, and validation across the product lifecycle. Because no universal reference material exists that captures the full diversity of process-specific HCPs, laboratories typically develop in-house reference standards from mock or null cell harvests, or use qualified commercial HCP preparations for early-phase work. These standards are characterized extensively for antibody coverage and stability, and lifecycle management includes bridging studies when a new lot or reagent is introduced. Regulatory expectations (e.g., USP <1132>) emphasize demonstrating that the assay remains comparable over time and across sites through the use of consistent reference materials, control samples, and documented coverage analyses.

• mAbs & Proteins: An essential release test. A process-specific assay (e.g., an anti-CHO HCP ELISA for a product made in CHO cells) is generally expected for commercial products, though platform ELISAs may be acceptable in early development or when adequate coverage and suitability are demonstrated.
• AAV Gene Therapy: A critical release test. Due to production in human cell lines (e.g., HEK293), the assay (an anti-HEK293 HCP ELISA) is critical for minimizing the risk of an immune response to residual host-cell derived proteins present from production and purification.
• CAR-T and Cell Therapies: If a protein product is expressed ex vivo (e.g., viral vector), HCP analysis may be performed on vector batches used in cell transduction.